Numis Securities Reiterates Buy Rating for Vectura Group (VEC)

Vectura Group (LON:VEC)‘s stock had its “buy” rating reiterated by analysts at Numis Securities in a note issued to investors on Thursday. They presently have a GBX 170 ($2.27) target price on the stock. Numis Securities’ target price would suggest a potential upside of 44.19% from the company’s current price.

A number of other research analysts also recently issued reports on VEC. Peel Hunt reissued a “hold” rating and issued a GBX 160 ($2.14) price objective on shares of Vectura Group in a research note on Wednesday, September 6th. Citigroup dropped their price objective on Vectura Group from GBX 200 ($2.67) to GBX 180 ($2.41) and set a “buy” rating on the stock in a research note on Monday, September 18th. JPMorgan Chase & Co. dropped their price objective on Vectura Group from GBX 210 ($2.81) to GBX 180 ($2.41) and set an “overweight” rating on the stock in a research note on Thursday, September 21st. Shore Capital reissued a “buy” rating on shares of Vectura Group in a research note on Thursday, November 9th. Finally, Panmure Gordon reissued a “buy” rating and issued a GBX 150 ($2.01) price objective on shares of Vectura Group in a research note on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of GBX 174 ($2.33).

Vectura Group (VEC) opened at GBX 117.90 ($1.58) on Thursday. Vectura Group has a 52 week low of GBX 86.50 ($1.16) and a 52 week high of GBX 166.97 ($2.23).

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/06/numis-securities-reiterates-buy-rating-for-vectura-group-vec.html.

About Vectura Group

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply